호르몬 피임법 시장 규모, 점유율, 동향 분석 보고서 : 방법별, 호르몬별, 지역별, 부문별 예측(2024-2030년)

Hormonal Contraceptive Market Growth & Trends:

The global hormonal contraceptive market size is anticipated to reach USD 21.21 billion by 2030, growing at a CAGR of 4.01% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is expected to be driven by the introduction of innovative products and increasing awareness about reproductive health in emerging regions. More women in developing economies are using contraceptives due to the rise in government initiatives and programs, which is anticipated to accelerate market growth. For instance, according to the UN World Fertility and Family Planning 2022, in 2021, 1.9 billion women of reproductive age received some form of contraception to avoid pregnancy with 77% of women among them using modern contraceptive methods including implants, patches, IUDs, and others.

According to the State of World Population 2022, by UNFPO, globally, approximately 50% of all 121 million pregnancies each year are unwanted. As per the Seeing the Unseen report: The case for action in the neglected crisis of unintended pregnancy, more than 60% of unwanted pregnancies result in abortion and the projected 45% among them are unsafe. Hence, to avoid unsafe abortions, countries are spreading awareness about contraceptives, which is expected to propel industry growth.

Due to the highly competitive nature of the market, companies are making significant investments in research and development. They are also adopting various strategies such as mergers and acquisitions and expanding their product pipelines. For instance, in February 2022, Organon Group of Companies acquired rights of Mercilon and Marvelon, combined oral hormonal daily contraceptive pills from Bayer AG in the People's Republic of China, including Macau and Hong Kong. In addition, it has agreed to acquire rights in Vietnam to these products. This acquisition aims to provide global ownership rights of these brands, except in South Korea.

Hormonal Contraceptive Market Report Highlights:

• Based on method, the pill segment dominated the market in 2023 owing to the efficient and straightforward administration, readily accessible products, enhanced market awareness due to early introduction compared to long-acting reversible devices, and an approximate 99% effectiveness with proper usage, and the presence of many players contribute to the segment growth.
• Based on hormone, the combination hormonal contraceptive segment dominated the market in 2023 owing to the fewer side effects and lower chances of developing acne and related symptoms.
• North America region held the largest market share in 2023. This can be attributed to the existence of major players, a high proportion of unwanted pregnancies, high per capita income, and supportive government initiatives.
• In June 2023, Gedeon Richter UK Limited, a pharmaceutical company, acquired full distribution and marketing rights of a contraceptive range of branded generics from Consilient Health Ltd. for USD 35.17 million (Euro 32.5 million). This acquisition aims to provide this product at affordable prices across the UK.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Method
  • 1.2.2. Hormone
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
  • 1.8.2. Volume Price Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rise in government and NGO initiatives to promote contraceptive methods
    • 3.2.1.2. High unmet needs
    • 3.2.1.3. Increasing R&D investments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rapidly aging population and rising prevalence of infertility
    • 3.2.2.2. Adverse effects associated with the use of contraceptive drugs and devices
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Method Business Analysis

• 4.1. Method Market Share, 2023 & 2030
• 4.2. Method Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Method, 2018 to 2030 (USD Million)
• 4.4. Pill
  • 4.4.1. Pill market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. IUD
  • 4.5.1. IUD market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Injectable
  • 4.6.1. Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.7. Vaginal Ring
  • 4.7.1. Vaginal ring market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.8. Implant
  • 4.8.1. Implant market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.9. Patch
  • 4.9.1. Patch market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hormone Business Analysis

• 5.1. Hormone Market Share, 2023 & 2030
• 5.2. Hormone Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analyses, by Hormone, 2018 to 2030 (USD Million)
• 5.4. Combination Hormonal Contraceptives
  • 5.4.1. Combination hormonal contraceptives market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Progestin Only
  • 5.5.1. Progestin only market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regional Estimates & Trend Analysis by Method & Type

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 6.4. North America
  • 6.4.1. North America hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key country dynamic
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. U.S. hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key country dynamic
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Canada hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key country dynamic
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Mexico hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamic
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. UK
    • 6.5.3.1. Key country dynamic
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. UK hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key country dynamic
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. France hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key country dynamic
    • 6.5.5.2. Regulatory framework
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Italy hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key country dynamic
    • 6.5.6.2. Regulatory framework
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Spain hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key country dynamic
    • 6.5.7.2. Regulatory framework
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Denmark hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key country dynamic
    • 6.5.8.2. Regulatory framework
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Sweden hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key country dynamic
    • 6.5.9.2. Regulatory framework
    • 6.5.9.3. Competitive scenario
    • 6.5.9.4. Norway hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key country dynamic
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Japan hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key country dynamic
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. China hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key country dynamic
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. India hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamic
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key country dynamic
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Australia hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key country dynamic
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Thailand hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key country dynamic
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Brazil hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key country dynamic
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. Argentina hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key country dynamic
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. South Africa hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key country dynamic
    • 6.8.3.2. Regulatory framework
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Saudi Arabia hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key country dynamic
    • 6.8.4.2. Regulatory framework
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. UAE hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key country dynamic
    • 6.8.5.2. Regulatory framework
    • 6.8.5.3. Competitive scenario
    • 6.8.5.4. Kuwait hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AbbVie Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. Bayer AG
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. Organon group of companies.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Pfizer Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Afaxys, Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. Teva Pharmaceutical Industries Ltd.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. Agile Therapeutics
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Johnson & Johnson Services, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Lupin Pharmaceuticals, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Pregna International Limited.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product benchmarking
    • 7.5.10.4. Strategic initiatives